Novo Nordisk aims to submit hemophilia drug for approval this year
Phase III results have confirmed Novo Nordisk’s faith in concizumab, which treats hemophilia A and B, and the company is now expecting to submit the drug for regulatory approval in H2 2022.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Before the year is over, Novo Nordisk will have submitted hemophilia drug concizumab for review by regulatory authorities, the company reports in its first quarterly report for 2022 on Friday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
